WHAT IS CLAIMED IS:

1. A cold-adapted temperature sensitive virus strain EV71:eTLLβP20, EV71:TLLeC5 or TLLeCA16.

2. The cold-adapted temperature sensitive virus strain of claim 1, wherein the strain is EV71:eTLLβP20.

3. The cold-adapted temperature sensitive virus strain of claim 1, wherein the strain is EV71:TLLeC5.

4. The cold-adapted temperature sensitive virus strain of claim 1, wherein the strain is TLLeCA16.

5. A composition comprising one or more of the cold-adapted temperature sensitive virus strain of any one of claims 1 to 4.

6. The composition of claim 5 further comprising a cold-adapted temperature sensitive Enterovirus 71 strain EV71:TLLβP20.

7. The composition of claim 5 or 6 which further comprises a pharmaceutically acceptable carrier.

8. The composition of claim 5, 6 or 7 which further comprises an adjuvant.

9. The composition of any one of claims 5 to 8 which is a vaccine.

10. The composition of claim 9, wherein the vaccine is an oral live attenuated vaccine.

11. The composition of claim 9, wherein the vaccine is an inactivated vaccine.

12. A kit for immunization of a subject with of a cold-adapted temperature sensitive virus strain comprising the cold-adapted temperature sensitive virus strain of any one of claims

1 to 4 or an inactivated form thereof, or a composition of any one of claims 5 to 11, a pharmaceutically acceptable carrier, and an instructional material for the use thereof.

13. The kit of claim 12 which further comprises an applicator.

14. A method of making a vaccine comprising using the cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 or an inactivated form thereof.

15. A method of making a vaccine comprising using one or more nucleic acids comprising the nucleotide sequence set forth in SEQ ID NO:84, SEQ ID NO:86 or SEQ ID NO:88.

16. The method of claim 15 further comprising using a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:83.

17. Use of the cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 or an inactivated form thereof for vaccine development.

18. Use of one or more nucleic acids comprising the nucleotide sequence set forth in SEQ ID NO:84, SEQ ID NO:86 or SEQ ID NO:88 for vaccine development.

19. The use of claim 18 further comprising a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:83.

20. A cold-adapted temperature sensitive virus strain of any one of claims 1 to 4 or an inactivated form thereof for use in vaccine development.

21. A nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:84, SEQ ID NO:86 or SEQ ID NO:88 for use in vaccine development.

22. An isolated nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:84, SEQ ID NO:86 or SEQ ID NO:88.

23. A virus vector comprising the nucleotide sequence set forth in SEQ ID NO:84, SEQ ID NO:86 or SEQ ID NO:88.